查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750874

Remicade市場規模、佔有率、趨勢分析報告：按類型、適應症、分銷管道、地區、細分市場預測，2025-2030 年

Remicade Market Size, Share & Trends Analysis Report By Type (Branded, Biosimilar), By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

Remicade市場成長與趨勢

根據Grand View Research的最新報告，預計到2030年全球Remicade市場規模將達到26.2億美元，2025年至2030年期間的複合年成長率為-2.28%。

儘管品牌主導地位正在逐漸下降，Remicade克隆氏症和類風濕性關節炎等自體免疫疾病全球負擔的推動， Remicade（Infliximab）市場仍持續呈現需求。 Remicade 仍然是治療這些疾病的廣泛使用的生物製藥。然而，由於生物相似藥的進入和接受度不斷提高，以及監管政策和醫療保健成本效益策略的不斷演變，市場正在發生重大變化。

市場佔有率的下降與英夫利西Infliximab生物相似藥的廣泛應用密切相關。關鍵地區的專利到期導致生物相似藥的供應增加，尤其是在公共醫療體系力求控制成本的國家。這種轉變鼓勵了更廣泛的患者獲得治療，同時也加劇了價格競爭，並挑戰了原廠藥的地位。儘管如此， Remicade豐富的臨床經驗和醫生對其的熟悉程度支持了其應用，尤其是在複雜病例中。

市場成長機會依然存在，尤其是在生物製藥應用仍在不斷擴大的地區。在亞洲、拉丁美洲以及中東和非洲的一些市場，醫療基礎設施的改善以及人們對發炎性疾病的認知不斷提高，推動了對原廠生物製藥和生物相似藥的需求成長。此外，正在進行的臨床研究以及包括皮下給藥在內的Infliximab新劑型的研發，也正在推動治療格局的不斷演變。

包括楊森、賽爾群和輝瑞在內的參與Remicade研發的製藥公司正在透過諸如區域授權合約、核准後生產合作以及對真實世界證據的投資等策略來應對這一轉變。生物相似藥開發商也正在利用差異化策略，例如高濃度配方和共同銷售協議，來加強其市場滲透率。

Remicade市場報告重點

  • 根據類型，品牌藥物將在 2024 年以 52.8% 的銷售佔有率引領市場。這種主導地位歸功於醫生的強大信任、成熟的臨床數據、某些市場對生物相似藥的緩慢採用以及患者對品牌的信任。
  • 根據適應症，類風濕性關節炎領域在 2024 年佔據市場最大收入佔有率，達到 20.8%。
  • 根據銷售管道，醫院藥房部門在 2024 年佔據了最大的市場收入佔有率。這是因為直接獲得專科護理、強力的醫生推薦以及複雜的自體免疫疾病患者數量眾多，使得醫院藥房成為Remicade（Infliximab）的首選銷售管道。
  • 2024年3月，Celltrion宣布計畫將原廠藥Zymfentra引進美國市場。 Zymfentra是一種用於治療自體免疫疾病的藥物，其上市標誌著Celltrion在生物相似藥領域拓展產品組合策略中邁出的重要一步。此舉體現了該公司更廣泛的策略，即實現產品組合多元化，並利用其在生物製藥開發方面的專業知識拓展新的治療領域。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章Remicade市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章Remicade市場：按類型進行的業務分析

  • 2024 年及 2030 年各類型市場佔有率
  • 類型細分細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 品牌
  • 生物相似藥

第5章Remicade市場：按適應症進行的業務分析

  • 2024 年及 2030 年各適應症市場佔有率
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（2018-2030 年）
  • 類風濕性關節炎
  • 乾癬性關節炎
  • 克隆氏症
  • 潰瘍性大腸炎
  • 僵直性脊椎炎
  • 其他

第6章Remicade市場：按分銷管道進行的業務分析

  • 2024 年和 2030 年按分銷管道分類的市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第7章Remicade市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • Janssen Pharmaceuticals（Johnson &Johnson）;
    • Celltrion
    • Pfizer Inc.
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc.
    • Samsung Bioepis
Product Code: GVR-4-68040-584-4

Remicade Market Growth & Trends:

The global remicade market size is anticipated to reach USD 2.62 billion by 2030 and is projected to decline at a CAGR of -2.28% from 2025 to 2030, according to a new report by Grand View Research, Inc. Despite a gradual decline in brand dominance, the Remicade (infliximab) market continues to show sustained demand, driven by the global burden of autoimmune diseases such as Crohn's disease and rheumatoid arthritis. Remicade has remained a widely prescribed biologic for these conditions. However, the market is undergoing significant change due to the increasing entry and acceptance of biosimilars, supported by evolving regulatory policies and healthcare cost-effective strategies.

The decline in market share is closely tied to the broader availability of biosimilar infliximab options. With patents expiring in key regions, biosimilars have become more accessible, particularly in countries with public healthcare systems seeking cost savings. This shift is encouraging broader patient access to treatment while intensifying price competition, challenging the position of the original product. Still, Remicade's extensive clinical history and physician familiarity support its use, especially in complex cases.

Opportunities for market growth remain, especially in regions where biologic use is still expanding. In markets across Asia, Latin America, and parts of the Middle East and Africa, improvements in healthcare infrastructure and rising awareness of inflammatory diseases are driving increased demand for both originator biologics and biosimilars. Moreover, ongoing clinical research and new infliximab formulations, including subcutaneous delivery, contribute to the evolving therapeutic landscape.

Pharmaceutical companies involved in the Remicade industry, including Janssen, Celltrion, and Pfizer, are responding to these shifts with strategies such as regional licensing deals, post-approval manufacturing partnerships, and investment in real-world evidence. Biosimilar developers also leverage differentiation tactics, including high-concentration formulations and co-marketing agreements, to strengthen market entry.

Remicade Market Report Highlights:

  • Based on type, the branded segment led the market with the largest revenue share of 52.8% in 2024. This dominance is attributable to strong physician trust, established clinical data, slower biosimilar adoption in certain markets, and patient trust in the brand.
  • Based on indication, the rheumatoid arthritis segment led the market with the largest revenue share of 20.8% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024, due to their direct access to specialized treatments, strong physician recommendations, and higher patient volumes for complex autoimmune conditions, making them the preferred distribution channel for Remicade (infliximab).
  • In March 2024, Celltrion announced plans to introduce its original drug, Zymfentra, to the U.S. market. The launch of Zymfentra, a treatment for autoimmune diseases, marks a significant step in Celltrion's strategy to expand its portfolio beyond biosimilars. This move reflects the company's broader strategy to diversify its offerings and leverage its expertise in biologic drug development for new therapeutic areas.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Remicade Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Remicade Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.5. Biosimilar
    • 4.5.1. Biosimilar Market, 2018 - 2030 (USD Million)

Chapter 5. Remicade Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2030
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 5.4. Rheumatoid Arthritis
    • 5.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 5.5. Psoriatic Arthritis
    • 5.5.1. Psoriatic Arthritis Market, 2018 - 2030 (USD Million)
  • 5.6. Crohn's Disease
    • 5.6.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Ulcerative Colitis
    • 5.7.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 5.8. Ankylosing Spondylitis
    • 5.8.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Remicade Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Remicade Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Remicade Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Remicade Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Janssen Pharmaceuticals (Johnson & Johnson);
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Celltrion
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Boehringer Ingelheim Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Teva Pharmaceutical Industries Ltd
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Pfizer Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Samsung Bioepis
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Remicade market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 6. Global Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 9. North America Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 10. North America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 13. U.S. Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 15. Canada Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 16. Canada Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 18. Mexico Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 19. Mexico Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 22. Europe Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 23. Europe Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 25. UK Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 26. UK Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 29. Germany Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 31. France Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 32. France Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 34. Italy Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 35. Italy Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 37. Spain Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 38. Spain Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 40. Norway Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 41. Norway Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 43. Denmark Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 44. Denmark Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 46. Sweden Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 47. Sweden Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 53. Japan Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 54. Japan Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 56. China Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 57. China Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 59. India Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 60. India Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 62. Australia Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 63. Australia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 65. South Korea Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 66. South Korea Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 68. Thailand Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 69. Thailand Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 72. Latin America Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 73. Latin America Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 75. Brazil Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 76. Brazil Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 78. Argentina Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 79. Argentina Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Remicade market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 85. South Africa Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 86. South Africa Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 91. UAE Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 92. UAE Remicade market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Remicade market, by type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Remicade market, by indication, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Remicade market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Remicade market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and indication outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Remicade market dynamics
  • Fig. 12 Remicade market: Porter's five forces analysis
  • Fig. 13 Remicade market: PESTLE analysis
  • Fig. 14 Type market, 2018 - 2030 (USD Million)
  • Fig. 15 Branded market, 2018 - 2030 (USD Million)
  • Fig. 16 Biosimilar market, 2018 - 2030 (USD Million)
  • Fig. 17 Indication market, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 19 Psoriatic Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 20 Crohn's Diseases market, 2018 - 2030 (USD Million)
  • Fig. 21 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 22 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 25 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 27 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Remicade market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Remicade market, 2018 - 2030 (USD Million)
  • Fig. 32 US country dynamics
  • Fig. 33 US Remicade market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Remicade market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Remicade market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Remicade market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Remicade market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Remicade market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Remicade market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Remicade market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Remicade market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Remicade market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Remicade market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Remicade market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific Remicade market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Remicade market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Remicade market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Remicade market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Remicade market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Remicade market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Remicade market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Remicade market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Remicade market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Remicade market, 2018 - 2030 (USD Million)
  • Fig. 73 MEA Remicade market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Remicade market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Remicade market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Remicade market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Remicade market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework